Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 108

    Eton Pharma fails to win USFDA nod for conjunctivitis treatment

    Eton Pharma fails to win USFDA nod for conjunctivitis treatment

    Medical Dialogues Bureau14 July 2019 9:30 AM IST
    The company sold the U.S. rights to its EM-100 eye drop for treating itching associated with allergic conjunctivitis to Bausch Health Companies Inc in...
    Milestone payment from Sanofi to Schrödinger for providing molecular simulation, computational design expertise

    Milestone payment from Sanofi to Schrödinger for providing molecular simulation, computational design expertise

    Medical Dialogues Bureau14 July 2019 9:16 AM IST
    Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple...
    USFDA clears Centerline flagship product Intra-Operative Positioning System

    USFDA clears Centerline flagship product Intra-Operative Positioning System

    Medical Dialogues Bureau14 July 2019 9:15 AM IST
    CLEVELAND: Centerline Biomedical, Inc. (Centerline) has announced that the company has received 510(k) clearance from the United States Food and Drug...
    Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer

    Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer

    Medical Dialogues Bureau14 July 2019 9:00 AM IST
    Durham: Biomarck Pharmaceuticals, Ltd recently announced that a Phase 2 clinical study in advanced NSCLC has commenced. This study at 10 sites in...
    Biocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of Glasgow

    Biocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of Glasgow

    Medical Dialogues Bureau13 July 2019 12:55 PM IST
    A further donation of USD 2.5 million will go towards creating a new Professorial Chair to be named the Mazumdar-Shaw Chair of Precision Oncology....
    Dr Reddys gets 5 USFDA observations for Bollaram plant

    Dr Reddys gets 5 USFDA observations for Bollaram plant

    Farhat Nasim13 July 2019 12:25 PM IST
    "The audit of our active pharmaceutical ingredient (API) manufacturing plant 2 at Bollaram, Hyderabad by the United States Food and Drug...
    Sandoz launches SYMJEPI Injection in US to help treat allergic reactions

    Sandoz launches SYMJEPI Injection in US to help treat allergic reactions

    Medical Dialogues Bureau13 July 2019 9:32 AM IST
    SYMJEPI is a small, single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment...
    Valeo Pharma launches Onstryv for treating Parkinsons disease in Canada

    Valeo Pharma launches Onstryv for treating Parkinsons disease in Canada

    Medical Dialogues Bureau13 July 2019 9:30 AM IST
    Onstryv is a prescription medication that can now be obtained at pharmacies across Canada and is available in 50mg and 100mg tablets. Valeo Pharma’s...
    Reckitt Benckiser pays USD 1.4 billion to settle opioid treatment spat

    Reckitt Benckiser pays USD 1.4 billion to settle opioid treatment spat

    Medical Dialogues Bureau13 July 2019 9:00 AM IST
    London: British consumer health giant Reckitt Benckiser announced Thursday it will pay up to $1.4 billion (1.2 billion euros) to settle a dispute...
    FIRST: Intas Pharma launches Romiplostim to treat chronic ITP in India

    FIRST: Intas Pharma launches Romiplostim to treat chronic ITP in India

    Medical Dialogues Bureau12 July 2019 11:48 AM IST
    Romiplostim is one of the most efficacious agents with proven long-term benefits in chronic ITP, a release here said.Mumbai: Pharma Major, Intas...
    Piramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingers

    Piramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingers

    Medical Dialogues Bureau12 July 2019 9:15 AM IST
    Piramal Enterprises chairman Ajay Piramal in his address to the shareholders in the FY19 annual report said the company continues to build resilience...
    Sterling Group: Government scraps Dahej port contract given to absconding Sandesara brothers

    Sterling Group: Government scraps Dahej port contract given to absconding Sandesara brothers

    Medical Dialogues Bureau12 July 2019 9:11 AM IST
    The absconding promoters of the Sterling group-- Nitin and Chetan Sandesara--are alleged to have defrauded over Rs 14,500 crore of public money. Two...
    PrevNext

    Popular Stories

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    China offers tariff exemptions on US medical equipment amid virus outbreak

    China offers tariff exemptions on US medical equipment amid virus outbreak

    OncoStem Diagnostics named

    OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and...

    BA/BE study applications have to be processed in 15 days: CDSCO

    BA/BE study applications have to be processed in 15 days: CDSCO

    SMS Pharma updates against USFDA statement on Ranitidine

    SMS Pharma updates against USFDA statement on Ranitidine

    Paras Healthcare ties up with J K Hospital, plans Rs 50 crore investment for comprehensive services

    Paras Healthcare ties up with J K Hospital, plans Rs 50 crore investment for comprehensive services

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok